Invited Commentary: Advanced Anatomic and Molecular Imaging in Recurrent Prostate Cancer.
作者信息
Turkbey Baris
机构信息
From the Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, 10 Center Dr, Room B3B85, Bethesda, MD 20892.
出版信息
Radiographics. 2023 Dec;43(12):e230215. doi: 10.1148/rg.230215.
Abstract
摘要
相似文献
1
Invited Commentary: Advanced Anatomic and Molecular Imaging in Recurrent Prostate Cancer.
Radiographics. 2023 Dec;43(12):e230215. doi: 10.1148/rg.230215.
2
Management of biochemically recurrent prostate cancer: molecular imaging perspective.
World J Urol. 2018 Feb;36(2):321-322. doi: 10.1007/s00345-017-2127-0. Epub 2017 Nov 13.
3
Imaging Locally Advanced, Recurrent, and Metastatic Prostate Cancer: A Review.
JAMA Oncol. 2017 Oct 1;3(10):1415-1422. doi: 10.1001/jamaoncol.2016.5840.
4
Clinical Applications of Molecular Imaging in the Management of Prostate Cancer.
PET Clin. 2017 Apr;12(2):185-192. doi: 10.1016/j.cpet.2016.11.001. Epub 2017 Jan 16.
5
The role of MRI for detection and staging of radio- and focal therapy-recurrent prostate cancer.
World J Urol. 2019 Aug;37(8):1485-1490. doi: 10.1007/s00345-019-02677-y. Epub 2019 Feb 20.
6
A paradigm shift from anatomic to functional and molecular imaging in the detection of recurrent prostate cancer.
Future Oncol. 2014 Feb;10(3):457-74. doi: 10.2217/fon.13.196.
7
Prostate MR Imaging for Posttreatment Evaluation and Recurrence.
Radiol Clin North Am. 2018 Mar;56(2):263-275. doi: 10.1016/j.rcl.2017.10.008. Epub 2017 Nov 27.
8
Current Imaging Techniques for and Imaging Spectrum of Prostate Cancer Recurrence and Metastasis: A Pictorial Review.
Radiographics. 2020 May-Jun;40(3):709-726. doi: 10.1148/rg.2020190121. Epub 2020 Mar 20.
9
Functional and molecular imaging of localized and recurrent prostate cancer.
Eur J Nucl Med Mol Imaging. 2013 Jul;40 Suppl 1(Suppl 1):S48-59. doi: 10.1007/s00259-013-2419-6. Epub 2013 May 7.
10
[Comments on article "Usefulness of PET scans in diagnosing recurrent prostate cancer. Prostate with PSA level <5"].
Actas Urol Esp. 2009 Sep;33(8):841. doi: 10.1016/s0210-4806(09)72868-2.
本文引用的文献
1
MRI and PSMA PET/CT of Biochemical Recurrence of Prostate Cancer.
Radiographics. 2023 Dec;43(12):e230112. doi: 10.1148/rg.230112.
2
Ga-PSMA-11 PET/CT versus Ga-PSMA-11 PET/MRI for the detection of biochemically recurrent prostate cancer: a systematic review and meta-analysis.
Front Oncol. 2023 Aug 14;13:1216894. doi: 10.3389/fonc.2023.1216894. eCollection 2023.
3
ACR Appropriateness Criteria® Post-Treatment Follow-up of Prostate Cancer: 2022 Update.
J Am Coll Radiol. 2023 May;20(5S):S164-S186. doi: 10.1016/j.jacr.2023.02.012.
4
Histopathologically Validated Diagnostic Accuracy of PSMA-PET/CT in the Primary and Secondary Staging of Prostate Cancer and the Impact of PSMA-PET/CT on Clinical Management: A Systematic Review and Meta-analysis.
Semin Nucl Med. 2023 Sep;53(5):706-718. doi: 10.1053/j.semnuclmed.2023.02.006. Epub 2023 Mar 31.
5
Cancer statistics, 2023.
CA Cancer J Clin. 2023 Jan;73(1):17-48. doi: 10.3322/caac.21763.
6
Validation of F-rhPSMA-7 and F-rhPSMA-7.3 PET Imaging Results with Histopathology from Salvage Surgery in Patients with Biochemical Recurrence of Prostate Cancer.
J Nucl Med. 2022 Dec;63(12):1809-1814. doi: 10.2967/jnumed.121.263707. Epub 2022 Apr 7.
7
PET Imaging for Prostate Cancer.
Radiol Clin North Am. 2021 Sep;59(5):801-811. doi: 10.1016/j.rcl.2021.05.008.
8
A Comprehensive Assessment of Ga-PSMA-11 PET in Biochemically Recurrent Prostate Cancer: Results from a Prospective Multicenter Study on 2,005 Patients.
J Nucl Med. 2022 Apr;63(4):567-572. doi: 10.2967/jnumed.121.262412. Epub 2021 Jul 29.
9
Evaluating Biochemically Recurrent Prostate Cancer: Histologic Validation of F-DCFPyL PET/CT with Comparison to Multiparametric MRI.
Radiology. 2020 Sep;296(3):564-572. doi: 10.1148/radiol.2020192018. Epub 2020 Jul 7.
10
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.
N Engl J Med. 2016 Oct 13;375(15):1415-1424. doi: 10.1056/NEJMoa1606220. Epub 2016 Sep 14.
Zotero 插件